JBIO Jade Biosciences Inc

Price (delayed)

$17.74

Market cap

$875.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$821.24M

?
Relative Growth: Rel. Growth: 21
Relative Strength: Rel. Strength: 91
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses ...

Highlights
JBIO's EPS has soared by 96% year-on-year and by 37% since the previous quarter
JBIO's debt has soared by 118% YoY but it is down by 6% from the previous quarter
The quick ratio has plunged by 56% YoY and by 31% from the previous quarter
The net income has dropped by 52% year-on-year

Key stats

What are the main financial stats of JBIO

JBIO stock price

How has the Jade Biosciences stock price performed over time
Intraday
0.85%
1 week
-14.88%
1 month
-27.65%
1 year
146.05%
YTD
14.97%
QTD
26.26%

Financial performance

How have Jade Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$133.6M
Net income
-$129.61M
Gross margin
N/A
Net margin
N/A
JBIO's operating income has dropped by 87% year-on-year and by 18% since the previous quarter
The net income has dropped by 52% year-on-year

Price vs fundamentals

How does JBIO's price correlate with its fundamentals

Growth

What is Jade Biosciences's growth rate over time

Valuation

What is Jade Biosciences stock price valuation
P/E
N/A
P/B
2.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
JBIO's EPS has soared by 96% year-on-year and by 37% since the previous quarter
The price to book (P/B) is 95% more than the last 4 quarters average of 1.5
The company's equity fell by 11% QoQ

Efficiency

How efficient is Jade Biosciences business performance
The return on equity has surged by 69% year-on-year and by 21% since the previous quarter
The return on assets has surged by 51% year-on-year and by 21% since the previous quarter
The company's return on invested capital rose by 38% YoY and by 34% QoQ

Dividends

What is JBIO's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history

Special dividends are included in TTM DPS and yield

Financial health

How did Jade Biosciences financials performed over time
The quick ratio has plunged by 56% YoY and by 31% from the previous quarter
Jade Biosciences's current ratio has plunged by 55% YoY and by 32% from the previous quarter
JBIO's debt is 100% less than its equity
JBIO's debt has soared by 118% YoY but it is down by 6% from the previous quarter
The company's equity fell by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.